
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is a promising investment due to its strong performance in TETON-1 data for the use of Tyvaso in IPF, potential for nebulized Tyvaso to be used as monotherapy, and expected success in the regulatory filing for nebulized Tyvaso. Factors such as the company's strong IPF pipeline, the FDA's new single pivotal trial policy, and the potential for ralinepag to replace JNJ's selexipag with better convenience and tolerability, further support our positive outlook.
Bears say
United Therapeutics is facing potential challenges in expanding its Tyvaso product into treatments for pulmonary fibrosis, as there is uncertainty about how much of the observed benefit is due to direct antifibrotic activity versus treatment of accompanying pulmonary vascular disease. Additionally, while management has high hopes for its TRESMI drug, the FDA's support for its filing in different markets is unclear, leaving further potential for disappointment. This, along with uncertainties around upcoming catalysts and the company's compressed multiples compared to its peers, leads to a negative outlook on UTHR's financial future.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares